Technology Transfer News

21 January 2021
Dr Gergely Huszka (left) and Dr Florian Döring (rechts) work together with a motivated team on the success of the start-up XRnanotech.

XRnanotech: a Spin-off is launched!

XRnanotech, the latest PSI spin-off, is working on nanostructured X-ray optics that make the smallest things - the world of the nanometer - visible. Founded only a few months ago, the start-up already has numerous successes to its credit and is already in talks with its first customers and investors.

Read more
15 December 2020
Dr. Roger Herger - CEO & Founder maXerials AG

From synchrotron to CEO

Roger Herger wrote his diploma thesis and doctoral dissertation on X-ray diffraction of complex metal oxides at the Swiss Light Source (SLS) synchrotron. At the end of June 2020, he founded the high-tech startup maXerial, together with two business partners. Their goal: to combine industrial X-ray technology with artificial intelligence. We trace his path from research to entrepreneur and show how cutting-edge PSI know-how and laboratory-based X-ray technology ideally complement each other to solve the challenges of the Swiss high-tech industry by means of data-driven materials development.

Read more
30 November 2020
Agnese Carino, former doctoral student at PSI, developed a novel coating for small implants together with Medicoat AG. (Image source Arbeitswelt Aargau 4/2020)

From research at PSI to the Aargauer SME Medicoat AG

Even as a doctoral student at PSI, Agnese Carino wanted to put the findings of her research into practice and did not hesitate to present her business idea to the CEO of Medicoat AG, Philipp Gruner. She wanted to develop a novel coating for small implants, which accelerates the recovery of the patient, into a product. Supported by the Hightech Zentrum Aargau this was the starting point of the joint SNI project NanoCoat. Carino was awarded the Founder Fellowship by PSI for her business idea. This program supports the transition from promising research findings to marketable products. We are pleased that Dr. Carino is now working with Medicoat to advance the commercialization of this technology.

Read more
12 November 2020
SIF 2020: "it's time to innovate - NOW"

PSI at the Swiss Innovation Forum!

This year's Swiss Innovation Forum takes place from 17th - 19th November as a 3-day virtual conference. Under the motto "It's time to innovate - NOW" the focus is on creativity, innovation and technology. Which technological trends will conquer the market? And what impact will Covid-19 have on future innovations? These and other questions will be addressed at this year's Swiss Innovation Forum.

PSI will be there - visit us at our virtual booth and find out more about how the technology transfer centre ANAXAM uses state-of-the-art material analysis to support both industry and SMEs in optimising production methods and processes, thus creating the basis for innovations.

Read more
3 November 2020
Dr. Florian Döring, CEO and Founder of XRNanotech

PSI Spin-off XRNanotech wins Swiss BIC of CERN Technologies 2020

With its extraordinary X-ray optics, XRNanotech GmbH, PSI's latest spin-off, was able to convince the jury of the "Business Incubation Centre (BIC) of CERN Technologies" programme of Park Innovaare and prevail over the other finalists. As the winner of this programme, the start-up will receive CHF 50,000 as well as further support from the University of Applied Sciences Northwestern Switzerland, CERN and PSI.

Read more
22 October 2020
ADCs (Anbibody Drug Conjugates) consist of highly potent cytotoxic agents conjugated to antibodies through a specific linker. This molecular format enables the highly selective delivery of any payload to the diseased tissue, while healthy parts of the human body are spared.

Araris Biotech successfully closes CHF 15.2 Mio seed round

Araris, one of PSIs youngest spin-offs, today announced that they have successfully closed a CHF 15.2M seed round with a group of previous and new investors. The funds raised will allow the further development of the ADC linker technology licensed out by PSI and hopefully identify potent drug candidates.

Dr. Philipp Spycher, CEO of Araris Biotech AG began his entrepreneurial endeavors with the PSI Founder Fellowship that helped kick-start his ideas of building a business around the technology that he helped to develop at PSI.

PSI applauds this development and looks forward to a bright future for Araris.

Read more
6 October 2020
Smart Energy Applied Solutions

Technology Briefing: Smart Energy Applied Solutions

Wednesday, November 11, 2020, from 13:30 to 18:00

Empa, Überlandstrasse 129, 8600 Dübendorf  (Participation possible on site OR via Zoom)

Online registration:

The conference series aims at informing our industry and business partners about pressing issues of practical relevance. Speakers representing CSEM, Empa, PSI and industry will cover a well-balanced and practice-oriented overview of the latest technologies. The event also provides a platform for knowledge sharing and exchange of experiences, allowing the identification of potential cooperation and further innovation.

Read more
23 September 2020
The ANAXAM-Team (f.l.t.r.): CEO Dr. Christian Grünzweig, Matthias Wagner (CTO), Dr. Cynthia Chang (CSO), Philippe Würsch (Technician), and Prof. Dr. Frithjof Nolting, President ANAXAM.

ANAXAM on track for success!

Several months have now passed since the new technology transfer centre "ANAXAM" was founded. Under the management of Dr. Christian Grünzweig and in close cooperation with PSI, ANAXAM is on the road to success for industry - time for a brief review.

Read more
10 September 2020
From the Laboratory to the Clinic: PSI-researcher at work.

Debiopharm: New generation radionuclide therapy in the fight against lung cancer

Debio 1124 - a compound developed at PSI and out-licensed to the Swiss company Debiopharm - is being tested in a clinical phase I study in patients with small cell lung cancer, as Debiopharm has published in a press release. The peptide binds highly specifically to proteins found on tumour cells in this type of cancer. If Debio 1124 is coupled to a nuclide, it can be used both to detect the tumour with imaging procedures and therapeutically to destroy the tumour cells bound in this way.

Read more